BIO-TECHNE CORP

Bio‑Techne CFO’s mixed buy‑sell trade shows confidence amid market noise, balancing short‑term liquidity with long‑term upside.

CEO Kelderman Kim’s July 28 buy of 35,000 Bio‑Techne shares at $47.60 reflects insider confidence and a balanced, long‑term strategy amid a strong rally in the life‑sciences stock.

Bio‑Techne Corp insider buying signals confidence: President Steven Crouse’s 600‑share purchase reflects bullish outlook and may boost the stock toward its 52‑week high.

Bio‑Techne insider purchase: Director Herr Amy E. adds 6,636 shares at $47.60, signaling confidence amid sector dip and potential future product launches.

Bio‑Techne insider buys reveal cautious optimism: CFO’s 62k-share purchase at $47.60 signals long‑term confidence amid earnings growth and dividend potential.

CEO Kelderman Kim’s recent buy/sell of Bio‑Techne shares signals confidence, but large option holdings raise dilution risks—watch earnings for clarity.

Insider sale of 1,976 Bio‑Techne shares by Herr Amy E. on Feb 17, 2026 signals routine portfolio rebalancing amid recent product certification and upcoming option vesting dates—watch how this could influence short‑term liquidity and valuation.

Bio‑Techne insider trading: Herr Amy E.’s small 22‑share net purchase signals confidence amid Q2 2026 earnings, supporting a moderate bullish outlook for the protein‑science & cell‑therapy leader.

Insider buying shows confidence in Bio‑Techne’s 3‑D hydrogel launch, highlighting potential upside despite a high P/E and market volatility.